NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that its CombiMatrix group’s subsidiary, CombiMatrix Molecular Diagnostics (CMDX), has completed the clinical validation of and has launched the second version of its Constitutional Genetic Array Test (CA850). The test utilizes the company’s new Bacterial Artificial Chromosome (BAC) array, which includes over 200 new, validated probes obtained through the company’s partnership with The Center for Applied Genomics, in Toronto, Canada. The CA850 array now has the most comprehensive and robust clinically validated genomic coverage in the industry. The CA850, which can identify over 50 common genetic disorders in one test, has now been clinically validated for use in both postnatal and prenatal analyses by CMDX.
